Evidence map›Paper›PMID 33984016›Full record

ArticlePloS one2021

Intra-abdominal hypertension and abdominal compartment syndrome in the critically ill liver cirrhotic patient-prevalence and clinical outcomes. A multicentric retrospective cohort study in intensive care.

Rui Pereira, Maria Buglevski, Rui Perdigoto, Paulo Marcelino, Faouzi Saliba, Stijn Blot, Joel Starkopf

Registry-linked trialOpen access · goldAbstract readMulticenter Study
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05172531 (Efficacy and Safety Profile of Cisatracurium Besylate for Intra-abdominal Hypertensiona), which is not on this map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05172531 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Efficacy and Safety Profile of Cisatracurium Besylate for Intra-abdominal Hypertensiona: Single Center, Randomized, Controlled Trial

TypeinterventionalSponsorTianjin Nankai HospitalRan2022 to 2023Enrolled80ConditionsIntra-abdominal HypertensionArmsCisatracurium Besylate, saline 0.12ml/kg/hr
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Inferior Vena Cava Syndrome.ACG case reports journal · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Observational
  9. Intra-Abdominal Hypertension and Its Prognostic Impact on Mortality in Cirrhotic Patients with Ascites: The Role of Paracentesis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 4 countries.

Rui PereiraHospital de Curry Cabral, Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal.ORCID 0000-0002-3010-8384
Maria BuglevskiUniversity of Tartu, Tartu University Hospital, Tartu, Estonia.
Rui PerdigotoHospital de Curry Cabral, Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal.
Paulo MarcelinoHospital de Santa Marta, Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal.
Faouzi SalibaAP-HP Hôpital Paul Brousse, Université Paris Saclay, Villejuif, France.
Stijn BlotGhent University, Ghent, Belgium.
Joel StarkopfUniversity of Tartu, Tartu University Hospital, Tartu, Estonia.
Hospital Curry Cabral · PTTartu University Hospital · EEGhent University Hospital · BEHospital de Santa Marta · PTUniversité Paris-Saclay · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLiver cirrhosis and ascites are risk factors for intra-abdominal hypertension (IAH) and abdominal compartment syndrome (ACS); however, data is scarce. We aimed to determine the prevalence of IAH/ACS in a population of critically ill cirrhotic patients with acute medical illness in intensive care and to assess for risk factors and clinical outcomes.

methodsThis was a multicentric retrospective cohort study including two general ICUs and pooled data from a multicentric study between January 2009 and October 2019.

resultsA total of 9,345 patients were screened, and 95 were included in the analysis. Mean age was 56.7±1.3 years, and 79% were male. Liver cirrhosis etiology included alcohol in 45.3% and alcohol plus hepatitis C virus in 9.5%. Precipitating events included infection in 26% and bleeding in 21% of cases. Mean severity score MELD and SAPS II were 26.2±9.9 and 48.5±15.3, respectively, at ICU admission. The prevalence of IAH and ACS was respectively 82.1% and 23.2% with a mean value of maximum IAP of 16.0±5.7 mmHg and IAH grades: absent 17.9%, I 26.3%, II 33.7%, III 17.9%, and IV 4.2%. Independent risk factors for IAH were alcoholic cirrhosis (p = 0.01), West-Haven score (p = 0.01), and PaO2/FiO2 ratio (p = 0.02); as well as infection (p = 0.048) for ACS. Overall, 28-day mortality was 52.6% associated with higher IAP and ACS, and independent risk factors were MELD (p = 0.001), white blood cell count (p = 0.03), PaO2/FiO2 ratio (p = 0.03), and lactate concentration (p = 0.04) at ICU admission.

conclusionsThis study demonstrates a very high prevalence of IAH/ACS in the critically ill cirrhotic patient in intensive care. Increased IAP and ACS were associated with severity of disease and adverse outcomes and independent risk factors for IAH were alcoholic cirrhosis, hepatic encephalopathy and PO2/FiO2 ratio, as well as infection for ACS. Early diagnosis, prevention, and treatment of IAH/ACS might improve outcome in critically ill cirrhotic patients.

Indexed as

Critical IllnessAgedCritical CareFemaleHumansIntensive Care UnitsIntra-Abdominal HypertensionLiver CirrhosisMaleMiddle AgedPrevalenceRetrospective StudiesSeverity of Illness IndexTreatment Outcome

Identifiers

PMID33984016
PMCPMC8118291
OpenAlexW3162650709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.